Companies

Alumni
3T Biosciences is solving major bottleneck in the field of immunotherapy - identifying
Alumni
QuickFire
Challenge Winner
At Ab Initio, we are using a proprietary directed evolution engineering technology to
Alumni
Achelois’ mission is to develop effective and nontoxic therapeutics to inhibit tumors, and
Alumni
Adicet is developing a novell cell therapy platform.
Alumni
Targeting sensitized nerves to treat chronic & debilitating neurogenic disorders
Alumni
Agenovir is developing a novel class of nuclease-based anti-viral therapeutics for
Ankasa is developing proprietary formulations of WNT stem cell activators to enable self
Alumni
Annexon is developing novel therapeutics for neurodegenerative and autoimmune disorders.
Alumni
New Pathways for Next Generation Biological, Peptide and RNA Therapeutics.
Alumni
Audentes is a biotechnology company committed to the development and commercialization of
Using our patented technology, we safely activate a patient's own immune cells and pair
Alumni
Targeted medicines for neurodevelopmental disorders
Alumni
Our mission is to create antifibrotic treatment strategies that address a wide variety of
Boost Biomes is a platform technology company, our platform allows us to engineer
CarnaBio's goal is to develop novel methodologies to attack undruggable/ difficult targets